Mindset Pharma is a Toronto-based drug discovery company that aims to develop novel psychedelic drugs.
Mindset Pharma
“Mindset Pharma is a psychedelic-based drug discovery business creating novel, patent-pending psychedelic compounds for treatment-resistant neurological and psychiatric disorders.”
You can find their investor presentation here.
In April 2021, Mindset announced it closed a bought deal public offering for a total of $6 million US.
Mindset Pharma is registered on the CNSX under the ticker MSET.
Media
- Mindset Files Multiple Final Patent Applications on Its Novel Psilocybin-Inspired Compounds (press release, February 2021)
- Mindset Pharma Announces Filing of Groundbreaking Psilocybin Synthesis Patent (press release, July 2020)
Activities
B2B
B2C
Drug Discovery
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates
Company News
Mindset Pharma Announces Development of Novel, Optimized, Intranasal Formulation (GlobeNewswire, 29 June 2022)The Future of Psychedelic Medicine Will Be Drugs You’ve Never Heard Of (Motherboard, 24 January 2022)
This article, by the always excellent Shayla Love, discussed the next generation of novel psychedelics. Starting with the many discoveries of Sasha Shulgin, the article then dives deeper into the wishes and hopes of psychedelic companies.
Mindset Pharma Expands Benchmarking Data for First-Generation Psychedelics Through the COPE Program with InterVivo Solutions (BioSpace, 23 April 2024)
Mindset Pharma announced that under its Co-operative Psychedelics Evaluation Platform (COPE) further developed its first-generation psychedelics benchmarking data by establishing standard pharmacokinetic, brain penetration, and drug discrimination data and protocols across LSD, psilocybin, and 5-MeO-DMT.
Mindset Pharma is pursuing breakthroughs in the psychedelics field with the help of “hard science” (, 26 November 2021)